Ovarian Sertoli-Leydig cell tumours: How typical is their typical presentation?

被引:11
|
作者
Melero Cortes, Lidia Maria [1 ]
Martinez Maestre, M. Angeles [1 ]
Vieites Perez-Quintela, M. Begona [2 ]
Gambadauro, Pietro [3 ,4 ]
机构
[1] Virgen del Rocio Univ Hosp, Gynecol Div, C Manuel Siurot S-N, Seville, Spain
[2] Virgen del Rocio Univ Hosp, Pathol Dept, Seville, Spain
[3] Uppsala Univ Hosp, Ctr Reprod, Uppsala, Sweden
[4] Karolinska Inst, Dept Learning Informat Management & Eth LIME, Stockholm, Sweden
关键词
Ovarian tumours; Sertoli-Leydig cell tumour; gynaecological endocrinology; hyperandrogenism; abnormal uterine bleeding; fertility preservation; OF-THE-LITERATURE; CLINICOPATHOLOGICAL ANALYSIS; MANAGEMENT;
D O I
10.1080/01443615.2017.1291590
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ovarian Sertoli-Leydig cell tumours (OSLCT) are rare and typically present with androgenic manifestations in women of the 2nd-3rd decade. Out of 228 diagnoses of ovarian sex cord-stromal tumours recorded at an academic institution during a 14-year period, eight women were surgically treated for OSLCT. Patient mean age was 54.8years (range 19-81), five women being in the postmenopausal stage (62.5%). Only one woman presented with androgenic manifestations (12.5%), four with abnormal/postmenopausal uterine bleeding (50%), and three with abdominal pain (37.5%). Fertility sparing or radical surgery was performed depending on patient age and stage of disease. The only patient with an advanced disease (FIGO stage IV) was referred to palliative care postoperatively. The other seven were at FIGO stage I. Five of them were free from disease at a mean follow-up of 67months, while the remaining two were lost at follow-up. The youngest woman of the series, treated with fertility-preserving unilateral salpingo-oophorectomy at the age of 19, had two spontaneous pregnancies and deliveries of healthy babies during a 10-year follow-up period. In conclusion, our single institution 14-year experience demonstrates that the diagnosis of OSLCT is particularly challenging since many patients are older than expected and lack androgenic manifestations. Impact statement center dot What is already known on this subjectOvarian Sertoli-Leydig cell tumours (OSLCT) are rare and are thought to typically present with androgenic manifestations in women of the 2nd-3rd decade.center dot What the results of this study addOur single institution 14-year experience shows that a high proportion of women with ovarian Sertoli-Leydig cell tumours may not present with androgenic manifestations, and many of them also are in the postmenopausal stage. Most patients have a good prognosis and fertility-preserving surgery in younger women can lead to spontaneous pregnancies and deliveries of healthy children after treatment.center dot What are the implications of these findings for clinical practice and/or further researchThe diagnosis of OSLCT is particularly challenging and therefore not reached before surgery in most of the cases. However, while hysterectomy with bilateral salpingo-oophorectomy and surgical staging are recommended for women with higher stage or no fertility wish, fertility-sparing surgery should be considered in younger women with early disease. Therefore, further research should focus on non-invasive diagnosis possibly by means of laboratory or imaging techniques.
引用
收藏
页码:655 / 659
页数:5
相关论文
共 50 条
  • [21] Cervical embryonal rhabdomyosarcoma and ovarian Sertoli-Leydig cell tumor with congenital absence of unilateral ovary
    Sunku, Rubu
    Duggal, Rajan
    Patel, Firuza D.
    Rai, Bhavana
    Srinivasan, Radhika
    Nijhawan, Raje
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (03) : 654
  • [22] Characteristics and outcomes analysis of ovarian Sertoli-Leydig cell tumors (SLCTs): analysis of 15 patients
    Wang, Guangning
    Zhang, Ran
    Li, Chuan
    Chen, Aiping
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [23] Ovarian Sertoli-Leydig cell tumor with coexisting vaginal angiomyxoma: Case report and review of the literature
    Tampakoudis, P
    Zafrakas, M
    Kostopoulou, E
    Dragoumis, K
    Tsalikis, T
    Bontis, J
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2004, 25 (01) : 116 - 118
  • [24] Spectrum of DICER1 Germline Pathogenic Variants in Ovarian Sertoli-Leydig Cell Tumor
    De Paolis, Elisa
    Paragliola, Rosa Maria
    Concolino, Paola
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (09)
  • [25] Sertoli-Leydig Cell Tumor of Ovary-A Diagnostic Dilemma
    Dhanya, Rohini C. S.
    Padhi, Somanath
    Varghese, Renu G'Boy
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2014, 8 (03) : 127 - 129
  • [26] 18 Sertoli-leydig cell tumors of the ovary: analysis of a single institution database
    Li, Wei
    Yang, Shuli
    Su, Li
    Miao, Jinwei
    Wu, Yumei
    Zheng, Xingzheng
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2022, 43 (03) : 134 - 140
  • [27] A paradoxical inhibition of androgenic hyperproduction by a Sertoli-Leydig cell tumour ovary
    Amato, G
    Izzo, G
    Izzo, A
    HUMAN REPRODUCTION, 1995, 10 (11) : 2967 - 2969
  • [28] Pediatric ovarian Sertoli-Leydig cell tumors with heterologous rhabdomyosarcoma elements: Clinical case series and review of the literature
    Koo, Jane
    Garrington, Timothy P.
    Kerr, Karol
    Treece, Amy L.
    Cost, Carrye R.
    PEDIATRIC BLOOD & CANCER, 2020, 67 (10)
  • [29] Sertoli-Leydig cell tumour in an infertile patient after stimulated ovulation
    Chou, HH
    Lai, YM
    Lai, CH
    Hsueh, S
    Soong, YK
    HUMAN REPRODUCTION, 1997, 12 (05) : 1021 - 1023
  • [30] Sertoli-Leydig cell tumour in a 13-year-old girl
    Boettcher, Bettina
    Hinney, Bernd
    Keyser, Johanna
    Kuehnle, Ingrid
    Schweyer, Stefan
    Emons, Guenter
    GYNECOLOGICAL ENDOCRINOLOGY, 2011, 27 (02) : 107 - 109